Abstract 4599: Rationally designed allosteric EGFR degrader SC3499 (IN-207375) selectively eliminates mutant EGFR and overcomes osimertinib resistance in non-small cell lung cancer
Jihoon Choi, Jun Gyu Kim, Yu Jin Lee, Young Jun Park et autres
Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated remarkable therapeutic efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. However, acquired resistance often driven by secondary EGFR mutations remains a major clinical challenge. Although …
kr (code pays fourni par la source)
0 citations
Cancer Research